FILE 'HOME' ENTERED AT 12:31:02 ON 13 FEB 2007

=> **FIL REGISTRY**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:31:18 ON 13 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 FEB 2007 HIGHEST RN 920588-28-9
DICTIONARY FILE UPDATES: 12 FEB 2007 HIGHEST RN 920588-28-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> E "IRESSA"/CN 25

E1	1		IRESINOSIDE A/CN
E2	1		IRESINOSIDE B/CN
E3	1	-->	IRESSA/CN
E4	1		IRETIN/CN
E5	1		IRETOL/CN
E6	1		IREX 12/CN
E7	1		IREZ 160/CN
E8	1		IRF 168/CN
E9	1		IRF 905/CN
E10	1		IRF-1 TRANSCRIPTION FACTOR (INTERFERON REGULATORY FACTOR-1) (SHEEP)/CN
E11	1		IRF-2 TRANSCRIPTION FACTOR (SHEEP)/CN
E12	1		IRF-3/7 PROTEIN KINASE/CN
E13	1		IRF1 (HUMAN CLONE 1029A7)/CN
E14	1		IRF1 PROTEIN (MOUSE STRAIN FVB/N CLONE MGC:6190 IMAGE:3600525)/CN
E15	1		IRF1-PROV PROTEIN (XENOPUS TROPICALIS CLONE MGC:89137 IMAGE:7007367 GENE IRF1-PROV)/CN
E16	1		IRF2-PROV PROTEIN (XENOPUS LAEVIS CLONE MGC:78854 IMAGE:3403030 GENE IRF2-PROV)/CN
E17	1		IRF2-PROV PROTEIN (XENOPUS TROPICALIS CLONE MGC:79503 IMAGE:6977055 GENE IRF2-PROV)/CN
E18	1		IRF2BP1 PROTEIN (HUMAN CLONE IMAGE:2821841 GENE IRF2BP1)/CN
E19	1		IRF2BP2 PROTEIN (HUMAN CLONE IMAGE:3882977 GENE IRF2BP2)/CN
E20	1		IRF2BP2 PROTEIN (HUMAN CLONE IMAGE:5214452 GENE IRF2BP2)/CN
E21	1		IRF2BP2-A PROTEIN (XENOPUS LAEVIS CLONE MGC:53176 IMAGE:5543004)/CN

```
E22          1     IRF2BP2-PROV PROTEIN (XENOPUS TROPICALIS CLONE IMAGE:5309142
GENE IRF2BP2-PROV)/CN
E23          1     IRF3 PROTEIN (HUMAN CLONE MGC:15293 IMAGE:4135383)/CN
E24          1     IRF3 PROTEIN (HUMAN CLONE MGC:1716 IMAGE:3347928)/CN
E25          1     IRF3 PROTEIN (HUMAN CLONE MGC:88024 IMAGE:5494536)/CN

=> S E3
L1           1 IRESSA/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.55 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   184475-35-2  REGISTRY
CN   4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-
     morpholinyl)propoxy]- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-
     yl)propoxy]quinazolin-4-yl]amine
CN   4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-
     morpholinopropoxy)quinazoline
CN   Gefitinib
CN   Iressa
CN   ZD 1839
MF   C22 H24 Cl F N4 O3
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
       CASREACT, CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,
       MEDLINE, MRCK*, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  BIOL (Biological
       study); PROC (Process); USES (Uses)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1146 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1162 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> **file medline, caplus, wpids, uspatfull**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.80	8.01

FILE 'MEDLINE' ENTERED AT 12:32:21 ON 13 FEB 2007

FILE 'CAPLUS' ENTERED AT 12:32:21 ON 13 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 12:32:21 ON 13 FEB 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 12:32:21 ON 13 FEB 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> **s l1**
L2 2475 L1

=> **s l1 and hydroxyethylcellulose**
L3 9 L1 AND HYDROXYETHYLCELLULOSE

=> **d l3 1-9 ibib, abs, hitstr**

L3 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:308771 USPATFULL Full-text
TITLE: Compositions and methods for treatment for neoplasms
INVENTOR(S): Johansen, Lisa M., Belmont, MA, UNITED STATES
Lee, Margaret S., Middleton, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006264384	A1	20061123
APPLICATION INFO.:	US 2006-429544	A1	20060504 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-678078P	20050505 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 119 Drawing Page(s)
LINE COUNT: 1893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features compositions including two, three, or more agents useful in treating a patient with a neoplasm, methods for treatment of a patient with a neoplasm such as cancer (e.g., brain cancer), kits which include one, two, three, or more agents useful in the treatment of cancer, as well as methods for identifying combinations of compounds potentially useful in treating a patient with a neoplasm.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Gefitinib
(compns. and methods for treatment for neoplasms)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:196145 USPATFULL Full-text
TITLE: Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
INVENTOR(S): Yu, Ruey J., Chalfont, PA, UNITED STATES
Van Scott, Eugene J., Abington, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006166901	A1	20060727
APPLICATION INFO.:	US 2005-320530	A1	20051229 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-640225P	20050103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109, US
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 1682
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The embodiments described herein include a composition and method of treatment using compositions that include at least one O-acetylsalicyl derivative. The compositions and methods are useful in preventing and treating disorders and syndromes associated with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Gefitinib
(pharmaceutical compns. comprising acetylsalicyl derivs. of amino saccharides and amino acids)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:313136 USPATFULL Full-text
TITLE: Method for treating abnormal cell growth
INVENTOR(S): Denis, Louis J., Pawcatuck, CT, UNITED STATES
Compton, Linda D., Richland, MI, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005272755	A1	20051208	
APPLICATION INFO.:	US 2005-145097	A1	20050603	(11)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2004-577268P	20040604	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612, US
NUMBER OF CLAIMS: 95
EXEMPLARY CLAIM: 1
LINE COUNT: 2926
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase

inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Iressa
(camptothecin compds., pyrimidine derivs., and antitumor agents for treatment of abnormal cell growth)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:306550 USPATFULL Full-text
TITLE: Diindolylmethane formulations for the treatment of leiomyomas
INVENTOR(S): Zeligs, Michael A., Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005267193	A1	20051201
APPLICATION INFO.:	US 2005-124571	A1	20050506 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-569478P	20040506 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1848
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane and diindolylmethane-related indole. The present invention also relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane in combination with an EGFR antagonist. The methods provide non-invasive treatments for leiomyomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Iressa

(diindolylmethane formulations for treatment of leiomyoma)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:255665 USPATFULL Full-text
TITLE: Combinations of signal transduction inhibitors
INVENTOR(S): Eck, Stephen Louis, Ann Arbor, MI, UNITED STATES
Fry, David William, Ypsilanti, MI, UNITED STATES
Leopold, Judith Ann, Ann Arbor, MI, UNITED STATES
PATENT ASSIGNEE(S): PFIZER INC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005222163	A1	20051006
APPLICATION INFO.:	US 2005-95442	A1	20050330 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-557623P	20040330 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10777 SCIENCE CENTER DRIVE, SAN DIEGO, CA, 92121, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 3071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl- pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo- phenylamino)-

benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Iressa
(combinations of signal transduction inhibitors)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2005:226569 USPATFULL Full-text
TITLE:	Bioavailability and improved delivery of alkaline pharmaceutical drugs
INVENTOR(S):	Yu, Ruey J., Chalfont, PA, UNITED STATES Van Scott, Eugene J., Abington, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005196418	A1	20050908
APPLICATION INFO.:	US 2005-50434	A1	20050204 (11)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-792273, filed on 4 Mar 2004, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109, US
NUMBER OF CLAIMS:	52
EXEMPLARY CLAIM:	1
LINE COUNT:	1617

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Embodiments of the invention relate to a composition, a process of making the composition, and to the use of the composition. The compositions include a molecular complex formed between an alkaline pharmaceutical drug and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compositions provide improved bioavailability and improved delivery of the drug into the cutaneous tissues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Gefitinib

(bioavailability and improved delivery of alkaline drugs by complexation with acids or lactones)

RN 184475-35-2 USPATFULL

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2005:188926 USPATFULL Full-text

TITLE: Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative

INVENTOR(S): Gellert, Paul Richard, Cheshire, UNITED KINGDOM
De Matas, Marcel, Cheshire, UNITED KINGDOM
Parker, Michael Davis, Cheshire, UNITED KINGDOM

PATENT ASSIGNEE(S): AstraZeneca AB, Sodertalje, SWEDEN, SE-151 85 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005163835	A1	20050728	
APPLICATION INFO.:	US 2003-505231	A1	20030224	(10)
	WO 2003-GB803		20030224	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-4392	20020226
	GB 2003-212462	20020530
	GB 2003-213267	20020611

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US

NUMBER OF CLAIMS: 19

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 1537

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and a water-soluble cellulose ether or an ester of a water-soluble cellulose ether. The water-soluble cellulose ether or ester of a water-soluble cellulose ether present in the composition inhibits the rate of precipitation of the Agent from solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2P, ZD1839
(novel crystalline forms of anti-cancer compound ZD1839)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



(novel cryst. forms of anti-cancer compd. ZD1839)

L3 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:326927 USPATFULL Full-text
TITLE: Tumor-targeted drug delivery systems and uses thereof
INVENTOR(S): Ponzoni, Mirco, Genoa, ITALY
Corti, Angelo, Bergamo, ITALY
Allen, Theresa M., Edmonton, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004258747	A1	20041223
APPLICATION INFO.:	US 2004-853895	A1	20040526 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-12309	20030529

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 2801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of

the tumor cell and tumor-associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Iressa
(tumor-targeted drug delivery systems)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



L3 ANSWER 9 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:63317 USPATFULL Full-text
TITLE: Combinatorial drug therapy using polymer drug conjugates
INVENTOR(S): Bianco, James A., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Cell Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004047835	A1	20040311
APPLICATION INFO.:	US 2003-635970	A1	20030806 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-408591, filed on 6 Sep 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-409159P	20020909 (60)
	US 2002-419512P	20021018 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DONALD W. WYATT, CELL THERAPEUTICS, INC., 501 ELLIOTT AVENUE WEST, #400, SEATTLE, WA, 98119
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1843

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses combinations of drug conjugates with other therapeutic agents, including chemotherapy drugs. The invention also provides methods of using the combinations for the treatment of diseases associated with cell proliferation, such as tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 184475-35-2, Gefitinib
(polymer-drug conjugates for combination antiproliferative drug therapy)
RN 184475-35-2 USPATFULL
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



=> **d his**

(FILE 'HOME' ENTERED AT 12:31:02 ON 13 FEB 2007)

FILE 'REGISTRY' ENTERED AT 12:31:18 ON 13 FEB 2007
E "IRESSA"/CN 25
L1 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:32:21 ON 13 FEB 2007
L2 2475 S L1
L3 9 S L1 AND HYDROXYETHYLCELLULOSE

=> **s l2 and hydroxypropylcellulose**
L4 10 L2 AND HYDROXYPROPYLCELLULOSE

=> **s l4 not py>2002**
L5 0 L4 NOT PY>2002

=> **d his**

(FILE 'HOME' ENTERED AT 12:31:02 ON 13 FEB 2007)

FILE 'REGISTRY' ENTERED AT 12:31:18 ON 13 FEB 2007
E "IRESSA"/CN 25
L1 1 S E3

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 12:32:21 ON 13 FEB

```
     2007
L2          2475 S L1
L3             9 S L1 AND HYDROXYETHYLCELLULOSE
L4            10 S L2 AND HYDROXYPROPYLCELLULOSE
L5             0 S L4 NOT PY>2002

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    65.92      73.93

STN INTERNATIONAL LOGOFF AT 12:35:22 ON 13 FEB 2007
```